Future Outlook: Pfizer is currently focusing on a once-daily formulation with the hope of reducing side effects and improving tolerability
While long-term human outcome data remains limited, early findings indicate it may support metabolic resilience during energy deficits
Gyuraszova M, Kovalcikova A, Jansakova K, Sebekova K, Celec P, Tothova L
Differential morphological diagnosis of various forms of congenital hyperinsulinism in children
The path forward for cortistatin likely requires development of selective analogs with improved pharmacokinetics and a clinically feasible administration route
Christodoulaki C, Trakakis E, Pergialiotis V, et al